Perspective Therapeutics, Inc.
CATX
$2.17
-$0.03-1.14%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 209.00K | 290.00K | 342.00K | 234.00K | 369.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 209.00K | 290.00K | 342.00K | 234.00K | 369.00K |
| Cost of Revenue | 20.34M | 16.62M | 13.44M | 10.67M | 12.03M |
| Gross Profit | -20.13M | -16.33M | -13.09M | -10.44M | -11.66M |
| SG&A Expenses | 7.73M | 7.71M | 7.84M | 8.25M | 6.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.07M | 24.33M | 22.17M | 21.13M | 19.00M |
| Operating Income | -27.86M | -24.04M | -21.83M | -20.90M | -18.63M |
| Income Before Tax | -25.97M | -22.00M | -18.18M | -42.21M | -15.12M |
| Income Tax Expenses | -- | -- | -- | -2.10M | -- |
| Earnings from Continuing Operations | -25.97M | -22.00M | -18.18M | -40.11M | -15.12M |
| Earnings from Discontinued Operations | -- | 514.00K | -- | -59.00K | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.97M | -21.49M | -18.18M | -40.17M | -15.12M |
| EBIT | -27.86M | -24.04M | -21.83M | -20.90M | -18.63M |
| EBITDA | -27.09M | -23.31M | -21.10M | -40.38M | -17.97M |
| EPS Basic | -0.35 | -0.29 | -0.25 | -0.57 | -0.21 |
| Normalized Basic EPS | -0.22 | -0.19 | -0.16 | -0.16 | -0.13 |
| EPS Diluted | -0.35 | -0.29 | -0.25 | -1.14 | -0.21 |
| Normalized Diluted EPS | -0.22 | -0.19 | -0.16 | -0.16 | -0.13 |
| Average Basic Shares Outstanding | 74.30M | 74.24M | 72.36M | 70.82M | 70.63M |
| Average Diluted Shares Outstanding | 74.30M | 74.24M | 72.36M | 70.82M | 70.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |